中线外周T细胞淋巴瘤长期随访结果(附56例临床分析)  

Long term results of 56 patients with centrofacial T cell lymphoma

作　　者：许峰[1] 王瑾[1] 吴双[1] 林力[1] 杨家林[1] 王静波[1] 

机构地区：[1]四川省肿瘤医院放射治疗科,成都610041

出　　处：《中华放射肿瘤学杂志》1999年第4期201-203,共3页Chinese Journal of Radiation Oncology

摘　　要：目的　分析中线外周T细胞淋巴瘤( 原中线恶网) 的诊断、治疗结果及预后因素。方法　56 例中27 例进行免疫组化检查,所有病例均经过放射治疗,其中13 例配合化疗。结果　27 例免疫组织化学检查中19 例为T 细胞来源,1 例为B细胞来源,7 例不能分型。3,5,10 年生存率分别为59.2% ,51 .1% 和46 .0% 。全身(B) 症状、颈淋巴结侵犯及放射治疗剂量是影响生存率的重要因素。结论　原中线恶网多为结外侵犯的外周T 细胞淋巴瘤,放射治疗是局部首选的治疗方法,影响预后的重要因素为B症状。Objective To study the diagnosis, treatment results and prognostic factors of centrofacial T lymphoma (midline malignant reticulosis,MMR ). Methods From September 1987 to September 1996, 56 patients were initially diagnosed as having MMR or T cell lymphoma, of which 27 received immunophenotyping. All patients received radiotherapy, including 13 with alternating chemotherapy. Results Among the 27 patients with immunophenotyping, 19 were of T cell and 1 of B cell lineage, 7 could not be defined. The 3 ,5 and 10 year survival rates were 59.2%,51.1% and 46.0%, respectively. Survival was doomed in patients with B symptoms,neck lymph node involvement and low radiation dose. Conclusions The former MMR were mostly extronodal peripheral T lymphoma. Radiotherapy is the treatment of choice for localized disease. B symptoms, lymph node enlargement, radiation dose are prognostic.

关 键 词：T细胞淋巴瘤 放射疗法 免疫组织化学 预后 

分 类 号：R733.1[医药卫生—肿瘤]